Briefing
Circulating tumor (ct)DNA-guided adjuvant atezolizumab (atezo) in muscle-invasive bladder cancer (MIBC): Exploratory analysis of ctDNA dynamics in the IMvigor011 trial.
Of patients first testing ctDNA-positive, 74.1% (281/379) did so within 24 weeks of radical cystectomy; early positivity and higher baseline concentration (median 0.27 MTM/mL) were associated with shorter investigator-assessed DFS. Atezolizumab decreased ctDNA levels between cycle 1 and 3 (log2 fold-change -0.4) while levels increased on placebo (log2 fold-change 0.5; Wilcoxon P=0.009). Clearance at cycle 3 or 5 was associated with improved DFS and OS.
- n: 379 patients who tested ctDNA-positive during surveillance; on-treatment dynamics in 165 atezolizumab and 83 placebo
- Assay: not named in the abstract (results reported as mean tumor molecules/mL)